Aging and age-related diseases are a major public health concern, driving interest in anti-aging research. While small molecules and natural compounds show promise in animals, clinical translation is limited. Recently, chimeric antigen receptor (CAR)-engineered immune cells have achieved breakthroughs in treating non-cancerous conditions like autoimmune diseases and organ fibrosis, highlighting their therapeutic potential. This review explains how the immune system counteracts aging through senescent cell clearance, reduction of pro-inflammatory environments, and secretion of regenerative factors. It synthesizes principles of immune cell-based anti-aging therapies, analyzing preclinical and clinical studies. Key challenges include limited target specificity, immunosuppressive microenvironments, and variability in cell source and function. Future progress will require multidisciplinary collaboration-incorporating nanotechnology, synthetic biology, and targeted delivery-with artificial intelligence accelerating the development of personalized anti-aging interventions. Cellular immunotherapies thus hold transformative potential for modulating aging and advancing precision medicine to extend global healthspan.
Guo et al. (Wed,) studied this question.